Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C

Journal of Surgical Oncology

Volumn 93, Issue 1, 2006, Pages 47-55

  Ogata, Yutaka ^a   Matono, Keiko ^a   Sasatomi, Teruo ^a   Ishibashi, Nobuya ^a   Torigoe, Shojiro ^a   Fukumitsu, Takamasa ^a   Mizobe, Tomoaki ^a   Yamashita, Natsumi ^b   Yanagawa, Takashi ^b   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

5 deoxy floorouridine (5 DFUR); Biochemical modulation; Capecitabine; Dihydropyrimidine dehydrogenase (DPD); dThdPase DPD ratio; Fitting multiple linear regression models

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; NONOXINOL 9; THYMIDINE PHOSPHORYLASE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LINEAR REGRESSION ANALYSIS; MALE; NEUTROPENIA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM CANCER; STROMA CELL; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLOXURIDINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOMYCIN; RECTAL NEOPLASMS; THYMIDINE PHOSPHORYLASE; UP-REGULATION;

EID: 29844434596     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.20390     Document Type: Article

References (26)

1. Kono H, Hara Y, Sugata S, et al.: Activation of 5′-deoxy-5- fluorouridine by thymidine phosphorylase in human tumor tissues. Chem Pharm Bull (Tokyo) 1983;31:175-178.
2. Miwa M, Ura M, Nishida M, et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues. Eur J Cancer 1998;34:1274-1281.
3. Nishida M, Hino A, Mori K, et al.: Preparation of anti-tumor thymidine phosphorylase monoclonal antibody useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996;19:1407-1411.
4. Takebayashi Y, Akiyama S, Akiba S, et al.: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Int 1996;88:1110-1117.
5. Haraguchi M, Furukawa T, Sumizawa T, et al.: Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 1993;53: 5680-5682.
6. Eda H, Fujimoto K, Watanabe S, et al.: Cytokines induce thymidine phosphirylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-338.
7. Eda H, Fujimoto K, Watanabe S, et al.: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 1993;84:341-347.
8. Tevaerai HT, Laurent PL, Suardet L, et al.: Interaction of interferon-α2a with 5′-deoxy-5-fluorouridine in colorectal cancer calls in vitro. Eur J Cancer 1992;28:368-372.
9. Schwartz EL, Hoffman M, O'Connor CJ, et al.: Stimulation of 5-fluorouracil metabolic activation by interferon-α2a in human colon carcinoma cells. Biochem Biophys Res Commun 1992;182: 1232-1239.
10. Tanaka Y, Endo M, Ouchi K, et al.: Augmentation of antitumor activity of 5′-deoxy-5-fluorouridine by IL-12 through the upregulation of pyrimidine nucleoside phosphorylase in murine tumor models. Eur J Cancer 1997;33:S176-S177.
11. Sawada N, Ishikawa T, Fukase Y, et al.: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-1019.
12. Etienne MC, Cheradame S, Milano G: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-1670.
13. Lowry OH, Rosebroough NJ, Farr AC, et al.: Protein measurement with the Polin phenol reagent. J Biol Chem 1951;193:265-275.
14. Mori K, Hasegawa M, Nishida M, et al.: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tissues. Int J Oncol 2000;17:33-38.
15. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
16. Becouarn Y, Ychou M, Ducreux M, et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-2744.
17. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-913.
18. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
19. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
20. Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
21. Scheithauer W, McKendrick J, Begbie S, et al.: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-1743.
22. Ishikawa T, Sekiguchi F, Fukase Y, et al.: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumor in human cancer xenografts. Cancer Res 1998;58:685-690.
23. Yamamoto Y, Toi M, Tominaga T: Prediction of the effect of 5′-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncolgy Rep 1996;3:863-865.
24. Nishimura G, Terada I, Kobayashi T, et al.: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncology Rep 2002;9:479-482.
25. Hofheinz RD, Hartmann JT, Willer A, et al.: Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: Results of an extended multicentre phase-I trial. Br J Cancer 2004;91:834-838.
26. Rao S, Cunningham D, Price T, et al.: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004;91:839-843.